Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment of neuromyelitis optica spectrum disorders
Andrew R. Romeo, Benjamin M. Segal
Current Opinion in Rheumatology (2019) Vol. 31, Iss. 3, pp. 250-255
Closed Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

The changing landscape of optic neuritis: a narrative review
Lindsey B. De Lott, Jeffrey L. Bennett, Fiona Costello
Journal of Neurology (2021) Vol. 269, Iss. 1, pp. 111-124
Open Access | Times Cited: 48
Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder
Alexander D. Smith, Tatum M. Moog, Katy W. Burgess, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 70, pp. 104498-104498
Closed Access | Times Cited: 19
Neuromyelitis optica spectrum disorders
Shabeer Ahmad Paul, Gouranga Prasad Mondal, Ramesh Bhattacharyya, et al.
Journal of the Neurological Sciences (2020) Vol. 420, pp. 117225-117225
Open Access | Times Cited: 46
CNS Inflammatory Demyelinating Disorders: MS, NMOSD and MOG Antibody Associated Disease
Jacqueline Rosenthal, Benjamin Hoffman, William R. Tyor
Journal of Investigative Medicine (2019) Vol. 68, Iss. 2, pp. 321-330
Open Access | Times Cited: 45
Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experience
Wenjuan Huang, Jingzi ZhangBao, Xuechun Chang, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 46, pp. 102542-102542
Closed Access | Times Cited: 33
A Comparative Review of Typical and Atypical Optic Neuritis: Advancements in Treatments, Diagnostics, and Prognosis
Noah J Spillers, Patrick M. Luther, Norris C Talbot, et al.
Cureus (2024)
Open Access | Times Cited: 4
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial
Jacqueline Palace, Dean M. Wingerchuk, Kazuo Fujihara, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 47, pp. 102641-102641
Open Access | Times Cited: 32
Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis
Sakdipat Songwisit, Punchika Kosiyakul, Jiraporn Jitprapaikulsan, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 29
Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects
Marta Waliszewska‐Prosół, Justyna Chojdak-Łukasiewicz, Sławomir Budrewićz, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 6, pp. 2801-2801
Open Access | Times Cited: 25
Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder
Wenjuan Huang, Liang Wang, Junhui Xia, et al.
European Journal of Neurology (2022) Vol. 29, Iss. 8, pp. 2343-2354
Closed Access | Times Cited: 18
Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease
Tetsuya Akaishi, Tatsuro Misu, Kazuo Fujihara, et al.
Journal of Neurology (2021) Vol. 269, Iss. 6, pp. 3136-3146
Open Access | Times Cited: 22
Autologous hematopoietic stem cell transplantation in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis
Fardin Nabizadeh, Soroush Masrouri, Hossein Sharifkazemi, et al.
Journal of Clinical Neuroscience (2022) Vol. 105, pp. 37-44
Closed Access | Times Cited: 12
Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience
Johann Sellner, Harald H. Sitte, Paulus Rommer
Drug Discovery Today (2021) Vol. 26, Iss. 7, pp. 1591-1601
Open Access | Times Cited: 14
Vaccination in neuromyelitis optica spectrum disorders: Friend or enemy?
Haobing Cai, Ran Zhou, Fei Jiang, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 58, pp. 103394-103394
Open Access | Times Cited: 12
Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review
Michela Ada Noris Ferilli, Roberto Paparella, Ilaria Morandini, et al.
Life (2021) Vol. 12, Iss. 1, pp. 19-19
Open Access | Times Cited: 12
Monoclonal antibodies in neuro-ophthalmology
Caroline C. Keehn, Arman Yazdian, Patrick J. Hunt, et al.
Saudi Journal of Ophthalmology (2024) Vol. 38, Iss. 1, pp. 13-24
Open Access | Times Cited: 1
The costs of care from a US claims database in patients with neuromyelitis optica spectrum disorder
Alex Exuzides, Daniel Sheinson, Páris Sidiropoulos, et al.
Journal of the Neurological Sciences (2021) Vol. 427, pp. 117553-117553
Closed Access | Times Cited: 10
Eculizumab in the Treatment of Neuromyelitis Optica Spectrum Disorder
Katrin Giglhuber, Achim Berthele
Immunotherapy (2020) Vol. 12, Iss. 14, pp. 1053-1066
Closed Access | Times Cited: 10
New advancements in the management of Neuromyelitis Optica spectrum disease: literature review
Padmaja Sudhakar, Khawla Abusamra, Mangayarkarasi Thandampallayam, et al.
Frontiers in Ophthalmology (2023) Vol. 3
Open Access | Times Cited: 3
Controversies in the management of neuromyelitis optica spectrum disorder
Alice Bruscolini, Maurizio La Cava, Fabiana Mallone, et al.
Expert Review of Neurotherapeutics (2019) Vol. 19, Iss. 11, pp. 1127-1133
Closed Access | Times Cited: 8
Prevalence of neuromyelitis optica spectrum disorder in antioquia between 2016 and 2018
Carolina Monsalve Muñoz, Verónica Patiño López, Carolina Restrepo-Aristizábal, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 60, pp. 103677-103677
Closed Access | Times Cited: 5
Immunosuppressant and neuromyelitis optica spectrum disorder: optimal treatment duration and risk of discontinuation
Rui Li, Cong Li, Qiao Huang, et al.
European Journal of Neurology (2022) Vol. 29, Iss. 9, pp. 2792-2800
Closed Access | Times Cited: 4
High-dose immunosuppressive therapy followed by haematopoietic stem cell transplantation as a method for the treatment of refractory forms of neuromyelitis optica spectrum disorder in children
N. V. Bronina, Bykova Ov, Г. О. Бронин, et al.
Neurology neuropsychiatry Psychosomatics (2024) Vol. 16, pp. 74-82
Open Access
Pediatric Neuroimaging of Multiple Sclerosis and Neuroinflammatory Diseases
Chloe Dunseath, Emma J. Bova, Elizabeth Wilson, et al.
Tomography (2024) Vol. 10, Iss. 12, pp. 2100-2127
Open Access
Plasmapheresis for NMOSD: Not a rescue therapy anymore!?
Rohit Bhatia, Radhakrishna Pedapati, Sidharth Chopra
Annals of Indian Academy of Neurology (2019) Vol. 22, Iss. 4, pp. 371-371
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top